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Background: Biopsy remains the gold standard for determining fibrosis stage in patients
with primary biliary cholangitis (PBC), but it is unavailable for most patients. We used data
from the 11 US health systems in the FibrOtic Liver Disease Consortium to explore
a combination of biochemical markers and electronic health record (EHR)-based diagnosis/
procedure codes (DPCs) to identify the presence of cirrhosis in PBC patients.
Methods: Histological fibrosis staging data were obtained from liver biopsies. Variables
considered for the model included demographics (age, gender, race, ethnicity), total bilirubin,
alkaline phosphatase, albumin, aspartate aminotransferase (AST) to platelet ratio index
(APRI), Fibrosis 4 (FIB4) index, AST to alanine aminotransferase (ALT) ratio, and >100
DPCs associated with cirrhosis/decompensated cirrhosis, categorized into ten clusters. Using
least absolute shrinkage and selection operator regression (LASSO), we derived and vali
dated cutoffs for identifying cirrhosis.
Results: Among 4328 PBC patients, 1350 (32%) had biopsy data; 121 (9%) were staged F4
(cirrhosis). DPC clusters (including codes related to cirrhosis and hepatocellular carcinoma
diagnoses/procedures), Hispanic ethnicity, ALP, AST/ALT ratio, and total bilirubin were
retained in the final model (AUROC=0.86 and 0.83 on learning and testing data, respec
tively); this model with two cutoffs divided patients into three categories (no cirrhosis,
indeterminate, and cirrhosis) with specificities of 81.8% (for no cirrhosis) and 80.3% (for
cirrhosis). A model excluding DPCs retained ALP, AST/ALT ratio, total bilirubin, Hispanic
ethnicity, and gender (AUROC=0.81 and 0.78 on learning and testing data, respectively).
Conclusion: An algorithm using laboratory results and DPCs can categorize a majority of
PBC patients as cirrhotic or noncirrhotic with high accuracy (with a small remaining group
of patients’ cirrhosis status indeterminate). In the absence of biopsy data, this EHR-based
model can be used to identify cirrhosis in cohorts of PBC patients for research and/or clinical
follow-up.
Keywords: primary biliary cirrhosis, cholangitis, race/gender/ethnicity, gender, ethnicity,
decompensated cirrhosis, ursodeoxycholic acid, UCDA

Introduction
Although biopsy remains the gold standard for determining liver damage, fibrosis,
and cirrhosis in patients with primary biliary cholangitis (PBC), it is invasive and
performed on a relatively small subset of patients. Transient elastography has
shown promise for use in PBC patients1,2 but has not been universally implemented
in health care systems that are not supported by specialty gastroenterology and
hepatology clinics. An efficient system to identify cirrhosis in PBC patients using
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data from electronic health records (EHR)—such as diag
nosis and procedure codes (DPCs), and laboratory results
—may inform epidemiologic research and clinical trials,
as well as the identification of subgroups of PBC patients
who could benefit from earlier intervention.
Biomarkers for liver fibrosis calculated from results of
laboratory tests, such as the Aspartate Aminotransferase to
Platelet Ratio Index (APRI) and Fibrosis-4 (FIB4), have
been well described and validated among patients with
viral hepatitis. However, the distinct etiology and natural
history of PBC mean that the ability of these biomarkers to
identify cirrhosis cannot be assumed, and there are cur
rently no studies developing or validating PBC-specific
cutoffs for cirrhosis. Likewise, elevated alkaline phospha
tase (ALP), total bilirubin, and the ratio of aspartate ami
notransferase to alanine aminotransferase (AST/ALT) are
known to be important prognostic markers for PBC pro
gression and response to treatment with ursodeoxycholic
acid (UDCA).3,4 It is likely that the inclusion of these
variables could increase the utility of any marker for
cirrhosis among patients with PBC.
The FibrOtic Liver Disease Consortium (FOLD) com
prises a cohort of more than 4000 PBC patients drawn
from 11 US health systems. We applied machine learning
techniques to develop and validate an automated algorithm
combining EHR-based data—including DPCs and routine
laboratory results—for the identification of cirrhosis
among patients with PBC.

Possible Covariates/Classifiers
Table 1 details covariates considered for the model,
including patient demographics (age, gender, race,
Hispanic ethnicity); total bilirubin; ALP and albumin
(classified in relation to “normal” as defined by the assay
used at each site); APRI; FIB4 index; and AST/ALT ratio.
We collected laboratory data, liver-related diagnosis and
procedure codes (International Classification of Diseases
Ninth and Tenth editions [ICD9/10] and Current
Procedural Terminology [CPT] codes), all measured
within six months before/after biopsy. In cases where
more than one laboratory result was available, the one
Table 1 Laboratory Data
Test

The FOLD Consortium has been previously described.3,5
Briefly, FOLD comprises 11 geographically diverse health
systems, representing four US Census Bureau-defined
regions of the US (Northeast, Midwest, Northwest, and
South). FOLD follows the guidelines of the US
Department of Health and Human Services for the protec
tion of human subjects. The study protocol was approved
by the Institutional Review Board of each participating site
(see Supplementary Table 1). All authors had access to the
study results and reviewed and approved the final
manuscript.

FOLD PBC patient identification methods have been pre
viously described.5 All cases were confirmed with chart
abstraction performed by trained medical abstractors. We
used EHR data to identify FOLD PBC patients who had
undergone liver biopsy. Fibrosis staging from biopsy
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Serum alkaline phosphatase

Four categories (normal, 1-<2

(ALP)

times ULN, 2-<3 times ULN, or
≥3 times ULN), as defined by the

Methods
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results was collected by abstraction from pathology
reports, and mapped to an F0–F4 equivalency scale:6 F0,
no fibrosis; F1, portal fibrosis without septa; F2, portal
fibrosis with few septa; F3, numerous septa without cir
rhosis; and F4, cirrhosis. FOLD hepatologists provided
adjudication of indeterminate cases. If the patient had
more than one biopsy, the biopsy with the highest fibrosis
stage was considered. The outcome of interest was
a biopsy with F4/cirrhosis biopsy staging.

assay used at each FOLD site
Ratio of aspartate

Four categories (unknown; <1.1;

aminotransferase (AST) to

1.1-<2.2; ≥2.2) when tests were

alanine aminotransferase (ALT)

available within 7 days of one
another

Albumin

Normal or abnormal, as defined
by the assay used at each FOLD
site

Total bilirubin

Seven categories (≤0.4, >0.4–0.5,
>0.5–0.7, >0.7–1.0, >1.0–1.5,
>1.5–2.0, >2.0 mg/dL)

AST to Platelet Ratio Index
(APRI)

Numerical value, when tests
were available within 7 days of
one another

Fibrosis 4 Index (FIB4)

Numerical value, when tests
were available within 7 days of
one another

Platelet count

Numerical value

Clinical Epidemiology 2020:12
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closest to the date of biopsy was used. ICD9/10 and CPT
codes were grouped into ten clusters (C1 to C10, detailed
in Table 2); these were used as dichotomized (presence/
absence) variables in the classification analysis. An
“unknown” category was used for all variables that had
missing data.
Table 2 ICD-9/10 and CPT Codes Comprising the Ten Cluster
Variables (C1–C10)
Conditions

Associated ICD-9/10 and CPT
Codes

C1: Liver transplant

V42.7, 996.82, 50.5, 50.51, 50.59,
47135, 47136, T86.40, T86.41,
T86.42, 0FY00Z0,0FY00Z1,
0FY00Z2

C2: Liver cancer

155.0, 155.1, 155.2, C22.0, C22.2,
C22.7, C22.8, C22.1, C22.9

C3: Hepatorenal syndrome

572.4, K76.7

C4: Hepatic encephalopathy

572.2, K72.09, K72.91

C5: Portal hypertension/portal

572.3, 37140, 37160, 37180,

decompression procedures

37181, 37182, 37183, K76.6

C6: Esophageal varices

456.0, 456.20, 42.91, 44.91, 96.06,

complications (bleeding) and

43204, 43205, 43243, 43244,

procedures

43400, 43401, I85.01, I85.11,
06L30CZ, 06L30DZ, 06L30ZZ,
06L33CZ, 06L33DZ, 06L33ZZ,
06L34CZ, 06L34DZ, 06L34ZZ,
06L20ZZ, 06L23ZZ, 06L24ZZ,
0DL57DZ, 0DL58DZ

C7: Other gastrointestinal

530.7, 530.82, 578.0, 578.1, 578.9,

hemorrhage

K22.6, K22.8, K92.0, K92.1, K92.2

C8: Ascites/paracentesis

789.5, 789.59, 54.91, 49080,

procedures

49081, 49082, 49083, R18.8,
0D9S30Z, 0D9S3ZZ, 0D9S40Z,
0D9S4ZZ, 0D9T30Z, 0D9T3ZZ,
0D9T40Z, 0D9T4ZZ, 0D9V30Z,
0D9V3ZZ, 0D9V40Z, 0D9V4ZZ,
0D9W30Z, 0D9W3ZZ,
0D9W40Z, 0D9W4ZZ,
0W9F30Z, 0W9F3ZZ, 0W9F40Z,
0W9F4ZZ, 0W9G30Z,
0W9G3ZZ, 0W9G40Z,
0W9G4ZZ, 0W9J30Z, 0W9J3ZZ

C9: Other sequelae of chronic

572.8, K72.10, K72.90

liver disease
C10: Cirrhosis

571.2, 571.5, K70.30, K74.0,
K74.60, K74.69

Clinical Epidemiology 2020:12

Statistical Analysis
Data were randomly divided into two sets at a 2:1 ratio;
learning data (2/3) were used to build the classification
model and testing data (1/3) were used for model valida
tion. We performed analysis using machine learning
approaches to build the model, including SPM (Salford
Predictive Modeler, version 8.0) Least Absolute Shrinkage
and Selection Operator (LASSO)7 and several machineleaning R packages,8 including Classification and
Regression Tree (CART), K-Nearest-Neighbor (KNN),
polynomial support vector machines (SVMs), neural net
works, random forest models, and eXtreme Gradient
Boosting (xgb)Trees.8–10
The model building process started with variable selec
tion for the initial multivariable model. Highly correlated
variables (eg, AST/ALT ratio, APRI, and FIB4) were fit into
the model one at a time with other covariates to determine
which would be selected. The same modeling approach was
repeated using laboratory data without DPCs, given that
FIB4 (a commonly used laboratory data-based biomarker)
has been used to identify cirrhosis among patients with
chronic hepatitis.6 The final modeling approach and multi
variable model were selected for optimal classification
accuracy (defined by the highest area under the receiver
operating characteristic curve [AUROC]). Final model
selection was based on classification accuracy in the valida
tion set, with estimation of model goodness-of-fit measured
by AUROC. Models are considered to have “reasonable”
and “good” accuracy when the AUROC is 70–80% and
80–90%, respectively. We also identified an optimal cutoff point to provide clinical utility to correctly classify
patients as either cirrhotic or non-cirrhotic.

Results
Among 4328 confirmed PBC patients observed from 2006
to 2016, 1350 (32%) had biopsy data with F0–F4 staging;
121 (9%) were histologically staged F4 (cirrhosis). The
median number of biopsies per patient was 1; 25th and
75th percentiles were 1 and 1 with a range of 1 to 7. Table
3 presents the two-group comparison for all covariates of
interest.
The LASSO approach—using three laboratory variables
(ALP, total bilirubin, AST/ALT), gender, and ethnicity—
had “good” model classification accuracy; AUROC was
0.81 (learning data) and 0.78 (testing data). The model
equation is expressed as: Lscore = −2.10444 - 0.0380115 [if
ALP normal] - 0.10366 [if ALP 1-<2*ULN] + 0.0703424
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Table 3 Two-Group Comparison for Covariates of Interest
Variables*

Response**
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Age in years

F0–3

F4

p-value

(N= 1229)

(N= 121)

56.4 ± 11.6

58.7 ± 10.2

0.041

Gender

Women
Men

1066 (87%)
163 (13%)

99 (82%)
22 (18%)

0.133

Race

Asian/ Native American/ Pacific Islander
Black/ African American
White

98 (8%)
109 (9%)
804 (65%)

6 (5%)
15 (12%)
88 (73%)

0.054

Unknown

218 (18%)

12 (10%)

Hispanic ethnicity

Yes
No
Unknown

366 (30%)
780 (63%)
83 (7%)

10 (8%)
99 (82%)
12 (10%)

<0.001

Alkaline phosphatase (x ULN)

Normal
[1, 2)*ULN

267 (22%)
482 (39%)

28 (23%)
40 (33%)

0.385

[2, 3)*ULN

206 (17%)

28 (23%)

≥3*ULN
Unknown

259 (21%)
15 (1%)

23 (19%)
2 (2%)

Normal
[1, 2)*ULN

561 (46%)
370 (30%)

38 (31%)
45 (37%)

[2, 3)*ULN
≥3*ULN

149 (12%)
146 (12%)

14 (12%)
24 (20%)

Unknown

3 (0%)

0 (0%)

Normal
[1, 2)*ULN
[2, 3)*ULN

429 (35%)
401 (33%)
162 (13%)

22 (18%)
33 (27%)
23 (19%)

≥3*ULN

184 (15%)

42 (35%)

Unknown

53 (4%)

1 (1%)

Normal
(0.5, 1.0)*LLN
(0.33, 0.5]*LLN

923 (75%)
99 (8%)
11 (1%)

68 (56%)
34 (28%)
6 (5%)

(0, 0.33]*LLN

143 (12%)

11 (9%)

Unknown

53 (4%)

2 (2%)

<1.1
1.1>2.2

839 (68%)
287 (23%)

36 (30%)
68 (56%)

≥2.2

37 (3%)

16 (13%)

Unknown

66 (5%)

1 (1%)

(0, 0.4)
(0.4, 0.5)

324 (26%)
139 (11%)

10 (8%)
7 (6%)

(0.5, 0.7)

204 (17%)

17 (14%)

(0.7, 1.0)
(1.0, 1.5)

208 (17%)
118 (10%)

16 (13%)
17 (14%)

(1.5, 2.0)

39 (3%)

12 (10%)

>2.0
Unknown

99 (8%)
98 (8%)

41 (34%)
1 (1%)

<LLN
Normal

268 (22%)
720 (59%)

51 (42%)
40 (33%)

Unknown

241 (20%)

30 (25%)

Alanine aminotransferase (x ULN)

Aspartate aminotransferase (x ULN)

Platelet count (x LLN)

AST/ALT Ratio

Total Bilirubin (IU/L)

Albumin (xLLN)

0.013

<0.001

<0.001

<0.001

<0.001

<0.001

(Continued)
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Variables*

Response**

F0–3

F4

(N= 1229)

(N= 121)

p-value

C1

No
Yes

1199 (98%)
30 (2%)

97 (80%)
24 (20%)

<0.001

C2

No
Yes

1211 (99%)
18 (1%)

119 (98%)
2 (2%)

0.87

C3

No
Yes

1222 (99%)
7 (1%)

116 (96%)
5 (4%)

<0.001

C4

No
Yes

1206 (98%)
23 (2%)

108 (89%)
13 (11%)

<0.001

C5

No
Yes

1180 (96%)
49 (4%)

100 (83%)
21 (17%)

<0.001

C6

No
Yes

1211 (99%)
18 (1%)

112 (93%)
9 (7%)

<0.001

C7

No
Yes

1182 (96%)
47 (4%)

109 (90%)
12 (10%)

0.002

C8

No
Yes

1162 (95%)
67 (5%)

88 (73%)
33 (27%)

<0.001

C9

No
Yes

1193 (97%)
36 (3%)

100 (83%)
21 (17%)

<0.001

C10 (≥2 records)

No
Yes

1066 (87%)
163 (13%)

53 (44%)
68 (56%)

<0.001

APRI
Aspartate aminotransferase (mean ±SD)

2.0 ± 4.6
82.7 ± 180.3

4.6 ± 12.6
220.0 ± 423.8

0.033
<0.001

Alkaline phosphatase (mean ±SD)

278.6 ± 232.6

304.7 ± 359.0

0.438

Platelet count (mean ±SD)
AST/ALT Ratio (mean ±SD)

211.6 ± 111.6
1.1 ± 1.0

158.4 ± 80.0
1.4 ± 0.7

<0.001
<0.001

Fibrosis-4 Index (mean ± SD)

10.8 ± 33.9

12.4 ± 29.6

0.634

Notes: *all data were collected within six months of the biopsy assessment. **determined based on the highest fibrosis stage biopsy results if multiple assessments were involved.

[if ALP 2-<3*ULN] - 0.0859862 [if ALP≥3*ULN] 0.0961179 [if male] + 0.0552183 [if non-Hispanic ethni
city] - 0.0557998 [if Hispanic ethnicity] - 0.0553804 [if
bilirubin ≤0.4] - 0.0701528 [if bilirubin 0.5>0.4] 0.0239056 [if bilirubin 0.7>0.5] - 0.0881663 [if bilirubin
1.0>0.7] + 0.0658567 [if bilirubin 1.5>1.0] + 0.115739 [if
bilirubin 2.0>1.5] + 0.136269 [if bilirubin >2.0] 0.0865529 [if AST/ALT<1.1] + 0.0898492 [if AST/ALT
1.1-<2.2] + 0.144404 [if AST/ALT ≥2.2]. At the optimal
cutoff of 0.1 in this model, sensitivity was 70% and speci
ficity was 72% based on validation results.
A LASSO model with three laboratory variables (ALP,
total bilirubin, AST/ALT), two DPC clusters for diagnosis of
hepatocellular carcinoma and cirrhosis, and ethnicity

Clinical Epidemiology 2020:12

(Hispanic yes/no) demonstrated the best performance; this
model reached “excellent” classification accuracy, with
AUROCs of 0.86 on learning data and 0.83 on testing data.
This model combining laboratory and DPC data had signifi
cantly better predictive ability (AUROC) compared to the
model using laboratory data without DPCs (p=0.001). The
equation for this final LASSO model is expressed as : Lscore =
−2.80400 + 0.303777 [if ALP 2-<3*ULN] - 1.11856 [if
Hispanic ethnicity] - 0.325175 [if bilirubin ≤0.4] + 0.28772
[if bilirubin >0.5-0.7 mg/dL] + 0.512881 [if bilirubin
>1.0-1.5 mg/dL] + 0.9406 [if bilirubin >1.5-2.0 mg/dL] +
0.756801 [if bilirubin >2.0 mg/dL] - 0.652222 [if AST/
ALT<1.1] + 0.645455 [if AST/ALT 1.1-<2.2] + 0.681193
[if AST/ALT ≥2.2] + 0.707349 [if diagnosis of hepatocellular
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carcinoma] + 1.3713 [if two diagnoses of cirrhosis]. A single
cut-off of 0.08 (derived from the formula Prob = 1.0/(1.0 +
exp(-score)) yielded sensitivity of 76% and specificity of
75% based on validation results. Two optimal cut-offs (0.07
and 0.10) divided patients into three groups—non-cirrhotic
(≤0.07); indeterminate 0.7≤0.10); and cirrhotic (>0.10)—and
yielded improved specificities of 81.8% for absence of cir
rhosis and 80.3% for presence of cirrhosis.
Other modelling approaches using the same covariates
reached similar or lower model classification accuracy
(Supplementary Table 2); performance of the xgbTree model
was similar to the LASSO model (AUROC=0.82 on testing
data) but required ten variables (age, gender, ethnicity, albu
min, ALP, AST/ALT ratio, total bilirubin, platelet count, and
DPCs related to hepatocellular carcinoma and cirrhosis), mak
ing this model less useful in the “real world” setting.

Discussion
Using data drawn from the FOLD consortium, we applied
machine learning methods to EHR-based laboratory results
and DPCs to develop and validate a method for identifying
cirrhosis among patients with PBC. Our previous work has
shown that cirrhosis is an important prognostic marker for
poor outcomes among patients with PBC.3–5 However, in
these analyses, cirrhosis identification was based on
a limited number of patients with biopsy data (32%).
Transient elastography has gradually begun to replace
biopsy, but has not yet been universally implemented,
especially in health systems without specialty hepatology
clinics; only 12% of patients in our real-world cohort had
elastography data available. Our EHR-based model could
help address that gap in the identification of PBC patients
with cirrhosis. The classification accuracy of our model
using both laboratory data and DPC codes was “good”
(AUROC=0.83 on testing data) and was significantly bet
ter than an alternate model using laboratory results without
DPCs. The combined model with two-optimal cuts (0.07
and 0.10) divided patients into three groups (cirrhotic and
non-cirrhotic, with a small group [<7%] as indeterminate);
this model yielded 81.8% specificity for the absence of
cirrhosis and 80.3% specificity for the presence of
cirrhosis.
We believe this is the first validated model for use of
EHR-based data for cirrhosis identification among PBC
patients. Although previously developed markers for cir
rhosis, such as APRI (which combines AST, ALT, and
platelet count) and FIB4 (which combines age, AST,
ALT, and platelet count), have been validated in
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populations with viral hepatitis, it is not clear if they are
optimized for use in patients with PBC. In a model repla
cing AST/ALT ratio with FIB4, classification accuracy
was moderate (AUROC=0.75 on testing data). Our analy
sis found that a combination of total bilirubin, ALP, and
AST/ALT ratio—rather than APRI, FIB4, or the individual
components of those markers—provided better accuracy
(AUROC=0.83 on testing data). In light of our recent
study showing that total bilirubin, ALP, and AST/ALT
ratio were independent risk factors for all-cause mortality
in patients with PBC,4 our current findings suggest that
these variables may be the most appropriate biomarkers
for cirrhosis and poor outcomes.
One limitation of our analysis is that—although the overall
model classification accuracy reached 83%—sensitivity and
specificity remained only moderate (75–76%) with the use of
a single cut-off (0.08). We addressed this issue with the use of
two cutoffs (0.07 and 0.10), which improved specificity to
>80% for determining the absence of cirrhosis and presence of
cirrhosis, and left only 6.8% of patients classified as “indeter
minate.” While the use of more extreme cutoffs (eg, 0.05 and
0.16) could yield specificity in the range of 85–88%, it would
classify more patients (28%) as indeterminate. Limitations to
this method can be further addressed by using a hierarchical
approach for cirrhosis identification: 1) cirrhosis determination
based on biopsy or transient elastography when available; 2)
use of our model with two cutoffs. Analyses can categorize
those patients who fall into the “indeterminate” group as
“unknown.” We have successfully implemented a similar
approach for cirrhosis identification in patients with viral
hepatitis.11,12 An additional unavoidable limitation of classifi
cation models that they are most accurate when applied to
a sample with patient characteristics similar to those used to
build the model. Likewise, this model will need to be validated
using external data from a similar patient population.
In conclusion, our study showed that a model using
EHR-based data can be used to efficiently identify PBC
patients with cirrhosis. Using a hierarchical approach that
also takes into consideration cirrhosis determination via
biopsy/transient elastography data, when such data are
available, we expect that this model will be useful for
research in patients with PBC, and could serve as
a quality improvement tool to ensure the best available
care for such patients. Our model may also be useful in the
identification of risk factors for decompensation in large
observational studies of patients with PBC. There are
interventions that mitigate risk of cirrhotic patients' pro
gression from compensated to decompensated cirrhosis,
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and poor outcomes of decompensation—this tool may help
clinicians identify and monitor such patients.

Clinical Epidemiology downloaded from https://www.dovepress.com/ by 150.198.64.203 on 17-Dec-2020
For personal use only.

Author Contributions
All authors made substantial contributions to conception
and design, acquisition of data, or analysis and interpreta
tion of data; took part in drafting the article or revising it
critically for important intellectual content; agreed to sub
mit to the current journal; gave final approval of the
version to be published; and agree to be accountable for
all aspects of the work.

Funding
The FOLD Consortium has previously received funding
from Intercept Pharmaceuticals Inc.

Disclosure
Stuart C. Gordon receives grant/research support from AbbVie
Pharmaceuticals, Conatus, CymaBay, Eiger Pharmaceuticals,
Eli Lilly, Genfit, Gilead Sciences, GlaxoSmithKline, Intercept
Pharmaceuticals, Merck, and Viking Therapeutics. Mei Lu,
Joseph A. Boscarino, Mark A. Schmidt, Yihe G. Daida, Jia Li,
Loralee B. Rupp, and Sheri Trudeau receive research grant
support from Gilead Sciences and Intercept Pharmaceuticals.
Carla V. Rodriguez-Watson owns stock in Gilead (<$5000).
Heather Anderson receives grant/research support from
Intercept Pharmaceuticals. Jeffrey J. VanWormer receives
grant/research support from Retrophin. Christopher
L. Bowlus receives grant/research support from AbbVie
Pharmaceuticals, Bristol-Myers-Squibb, CymaBay, Gilead
Biosciences, GlaxoSmithKline, Intercept Pharmaceuticals,
Merck,
Mirum,
Shire
Pharmaceuticals,
Takeda
Pharmaceuticals, TARGET Pharmasolutions, and has served
as an advisor for Bristol-Myers-Squibb, Gilead Biosciences,
Intercept Pharmaceuticals, and Takeda. Keith Lindor is
a consultant/advisor for Biopharma and has served as an ad
hoc advisor for HighTide, Takeda, Shire, and Intercept
Pharmaceuticals. He sits on a Data Safety Monitoring Board

Clinical Epidemiology

Lu et al

for Takeda. Robert J. Romanelli receives received grant/
research support from Pfizer Inc. and Janssen Scientific
Affairs. The authors report no other conflicts of interest in
this work.

References
1. Wong VW-S, Chan HL-Y. Transient elastography. J Gastroenterol
Hepatol. 2010;25(11):1726–1731. doi:10.1111/j.1440-1746.2010.06
437.x
2. Joshita S, Yamashita Y, Sugiura A, et al. Clinical utility of FibroScan
as a non-invasive diagnostic test for primary biliary cholangitis.
J Gastroenterol Hepatol. 2019.
3. Lu M, Zhou Y, Haller IV, et al. Increasing prevalence of primary
biliary cholangitis and reduced mortality with treatment. Clin
Gastroenterol Hepatol. 2018;16(8):1342–1350. doi:10.1016/j.cgh.
2017.12.033
4. Gordon SC, Wu KH, Lindor K, et al. Ursodeoxycholic acid treatment
preferentially improves overall survival among African Americans
with primary biliary cholangitis. Am J Gastroenterol. 2020;115
(2):262–270. doi:10.14309/ajg.0000000000000512
5. Lu M, Li J, Haller IV, et al. Factors associated with prevalence and
treatment of primary biliary cholangitis in United States health
systems. Clin Gastroenterol Hepatol. 2018;16(8):1333–1341.
doi:10.1016/j.cgh.2017.10.018
6. Li J, Gordon SC, Rupp LB, et al. The validity of serum markers for
fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21
(12):930–937. doi:10.1111/jvh.12224
7. CART 6.0 User’s Guide Salford Systems [computer program]. 2010.
8. Torsten H CRAN task view: machine learning & statistical learning.
2020. Available from: https://CRAN.R-project.org/view=
MachineLearning. Accessed October 1, 2020.
9. Friedman J, Hastie T, Tibshirani R. Additive logistic regression:
a statistical view of boosting (With discussion and a rejoinder by
the authors). Ann Statist. 2000;28(2):337–407. doi:10.1214/aos/
1016218223
10. Friedman JH. Greedy function approximation: A gradient boosting
machine. Ann Statist. 2001;29(5):1189–1232. doi:10.1214/aos/
1013203451
11. Li J,Zhang T, Gordon SC. Does Hepatitis C eradication lead to
improved glucose metabolism, renal and cardiovascular outcomes in
diabetic patients? American Association for the Study of Liver
Diseases (AASLD) 2017 Auunal Meeting. 2017:ID: 981.
12. Lu M, Wu KH, Li J, et al. Adjuvant ribavirin and longer direct-acting
antiviral treatment duration improve sustained virological response
among hepatitis C patients at risk of treatment failure. J Viral Hepat.
2019;26(10):1210–1217. doi:10.1111/jvh.13162

Dovepress

Publish your work in this journal
Clinical Epidemiology is an international, peer-reviewed, open access,
online journal focusing on disease and drug epidemiology, identifica
tion of risk factors and screening procedures to develop optimal pre
ventative initiatives and programs. Specific topics include: diagnosis,
prognosis, treatment, screening, prevention, risk factor modification,

systematic reviews, risk & safety of medical interventions, epidemiol
ogy & biostatistical methods, and evaluation of guidelines, translational
medicine, health policies & economic evaluations. The manuscript
management system is completely online and includes a very quick
and fair peer-review system, which is all easy to use.

Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journal

Clinical Epidemiology 2020:12

submit your manuscript | www.dovepress.com

DovePress

Powered by TCPDF (www.tcpdf.org)

1267

